LENZ Therapeutics, Inc.

Business Summary

Part I Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States (U.S.) Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the U.S. We...

Next Earnings

Q2 FY2026 — expected 2026-09-21

Key Facts from Earnings Calls

Annual Reports (10-K)

Quarterly Reports (10-Q)

Recent Current Reports (8-K)

89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

Company Identity

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API: